問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Cathay General Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 815

    Total Beds

  • 365

    Total Doctors

  • cathaydmr@gmail.com
  • Caleb Lin
  • 02-27082121#1082
  • 106Taipei CityDa An280 Renai Rd. Sec.4, Taipei

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

112Cases

2008-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack

  • Test Drug

    AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

2010-07-01 - 2013-07-01

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-11-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-12-01 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2017-01-01 - 2020-06-30

Phase III

A Phase 3 Multicenter, Randomized, Double-blind,Placebo-controlled Study with an Open Label Extension to Evaluatethe Efficacy and Safety of KHK4827 in Subjects with Axial Spondyloarthritis

  • Condition/Disease

    Axial Spondyloarthritis

  • Test Drug

    KHK4827 (Brodalumab)

Participate Sites
13Sites

Terminated11Sites

羅淑芬
Linkou Chang Gung Medical Foundation

黃春明
China Medical University Hospital-Taipei

未分科

2012-06-01 - 2014-08-31

Phase I/II

A Phase I/II, Open-label, Randomized, Active Control, Dose Finding Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 in Interferon-Naïve Subjects with Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Hepatitis B virus

  • Test Drug

    P1101

Participate Sites
9Sites

Terminated9Sites

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2011-06-01 - 2013-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Study ended9Sites

2024-08-26 - 2026-07-23

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 8 9 10 11 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB